In the present study, we applied a mouse-specific monoclonal antibody treatment regime targeting PD-L1 to investigate potential side effects of ICI therapy on the heart after recovery from tumor disease in the reversible B16F10 melanoma mouse model. The gene discussed is CD274; the disease is melanoma.